SMOFLipid vs Clinoleic - randomised controlled trial
Phase 4
Not yet recruiting
- Conditions
- Parenteral nutrition associated cholestasis and liver diseaseLate onset sepsisChronic lung diseasePatent ductus arteriosisPremature birth- Intra-ventricular haemorrhage
- Registration Number
- ACTRN12617000883314
- Lead Sponsor
- epean Hospital NIC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie SMOFLipid's impact on omega-3 fatty acid levels in preterm neonates with cholestasis?
How does SMOFLipid compare to Clinoleic in preventing parenteral nutrition-associated liver disease in <30 week preterm infants?
Which biomarkers correlate with improved outcomes in preterm neonates receiving fish oil-based lipid emulsions for cholestasis?
What adverse events are associated with long-chain omega-3 fatty acid supplementation via SMOFLipid in preterm infants?
Are there synergistic effects when combining SMOFLipid with enteral nutrition strategies to reduce chronic lung disease in preterm neonates?